Sign in Subscribe
Drugs

CIMA Labs and Zeneca Achieve Key Milestone in Migraine Treatment

Strategic Insights

— 1 min read

CIMA Labs, a leader in oral drug delivery systems, has reached a significant milestone in its collaboration with Zeneca, a global biopharmaceutical company. The partnership has led to the submission of a regulatory filing in Europe for Zeneca's migraine treatment, Zomig, in the form of an OraSolv fast-dissolve tablet. This achievement demonstrates the commitment of CIMA Labs to delivering high-quality products in a timely manner and solidifies its partnership with Zeneca.

Key Takeaways:

  • CIMA Labs and Zeneca have collaborated to develop an OraSolv fast-dissolve tablet of Zeneca's migraine treatment, Zomig, which has been submitted for regulatory review in Europe.
  • The partnership was established in September 1997, and the regulatory filing was submitted in just 16 months, highlighting the success of the collaboration.
  • John M. Siebert, Ph.D., President and Chief Executive Officer of CIMA Labs, praised Zeneca as an excellent partner and highlighted the significance of this achievement for CIMA Labs.
  • OraSolv is a patented oral dosage form designed to improve taste acceptance and address the difficulty of swallowing traditional tablets and capsules.
  • CIMA Labs specializes in oral drug delivery systems, including OraSolv, OraSolv SR/CR, DuraSolv, and OraVescent, aimed at improving patient compliance and drug efficacy.
  • Zeneca is a $8.6 billion international bioscience business engaged in the research, development, and marketing of pharmaceuticals, agricultural, and specialty chemical products.

Statistics:

  • 16 months: The time frame between signing the Development and License Option Agreement in September 1997 and submitting the regulatory filing.
  • $8.6 billion: The annual revenue of Zeneca Group PLC.
  • $4.66 billion: Worldwide sales of Zeneca Pharmaceuticals in 1998.
  • 1997: The year CIMA Labs and Zeneca established their partnership.
  • 1998: The year Zeneca reported its worldwide sales.

Sources:

  • CIMA LABS INC. press release, February 18 [no date specified]
  • Zeneca Group PLC (NYSE: ZEN)
  • "About Zeneca" [no date specified]

Read more